Many pathogenic cascades modeled in vivo—Aβ accumulation, tau hyperphosphorylation, synaptic dysfunction, neuroinflammation, lipid dysregulation, BBB impairment, glymphatic flow reduction and aging-related vulnerability—correspond directly to clinical biomarkers used to define AD, including CSF Aβ42, p-tau, neurofilament light chain, GFAP, TSPO-PET, and vascular MRI signatures [212,213,214]. Here, MAPT is linked to Alzheimer disease.